LCL161
99%
- Product Code: 202263
CAS:
1005342-46-0
| Molecular Weight: | 500.63 g./mol | Molecular Formula: | C₂₆H₃₃FN₄O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
LCL161 is primarily used in cancer research as a potent antagonist of inhibitor of apoptosis proteins (IAPs), particularly targeting cIAP1, cIAP2, and XIAP. By inhibiting these proteins, LCL161 promotes apoptosis in tumor cells, making it a candidate for investigation in various oncology applications. It has been studied in clinical trials for its ability to sensitize cancer cells to other therapies, including chemotherapy and radiation, especially in solid tumors and hematological malignancies. Its mechanism enhances TNFα-mediated cell death, which can be leveraged in combination treatments to improve therapeutic response. Research continues to explore optimal dosing, patient selection, and synergistic regimens in cancers such as melanoma, breast cancer, and leukemia.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿5,270.00 |
+
-
|
| 10mg | 10-20 days | ฿8,970.00 |
+
-
|
| 100mg | 10-20 days | ฿54,230.00 |
+
-
|
| 250mg | 10-20 days | ฿92,190.00 |
+
-
|
| 50mg | 10-20 days | ฿29,990.00 |
+
-
|
LCL161
LCL161 is primarily used in cancer research as a potent antagonist of inhibitor of apoptosis proteins (IAPs), particularly targeting cIAP1, cIAP2, and XIAP. By inhibiting these proteins, LCL161 promotes apoptosis in tumor cells, making it a candidate for investigation in various oncology applications. It has been studied in clinical trials for its ability to sensitize cancer cells to other therapies, including chemotherapy and radiation, especially in solid tumors and hematological malignancies. Its mechanism enhances TNFα-mediated cell death, which can be leveraged in combination treatments to improve therapeutic response. Research continues to explore optimal dosing, patient selection, and synergistic regimens in cancers such as melanoma, breast cancer, and leukemia.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :